PlainPharmaWatch

CMS Open Payments · Program Year 2024

Zambon USA Ltd.

Zambon USA Ltd. reported $62,496.14 across General Payments, Research, and Ownership to 99 physicians and teaching hospitals across 99 transactions.

$62.5K
All-tracks total
99
Transactions
99
Recipients
+$18.2K
General Payments vs PY2023

Zambon USA Ltd. reported $62,496.14 across all CMS Open Payments tracks (General + Research + Ownership) to 99 physicians and teaching hospitals in Program Year 2024 - ranking #1293 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $62,496.14, averaging $631.27 per recipient.

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer zambon-usa-ltd Zambon USA Ltd.

$62.5K · #1293/1,925 · 0.0% industry · PY2024

  • TOT $62.5K
  • RANK #1293
  • SHARE 0.0%
  • TXN 99
  • RCP 99
  • CAT 3
  • GEN $62.5K
  • ΔGEN +$18.2K
  • TOP1 12.3%
  • PY 2024

Nearest volume peer: Carbofix Spine Inc ($62.5K)

Cardinal Health Inc$62.6KZambon USA Ltd. (this)$62.5KCarbofix Spine Inc$62.5KSpineGuard, Inc.$62.4KPolyMedics Innovations Inc.$62.1K
All-tracks payment totals near Zambon USA Ltd. (CMS Open Payments PY2024)

Zambon USA Ltd. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Zambon USA Ltd.'s CMS-reported General Payments increased by $18.2K (+40.9%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: ZAMBON USA LTD.PY2023: ZAMBON USA LTD.PY2024: Zambon USA Ltd.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$44.3KPY2024$62.5K
PY2023
$44,340.58
PY2024
$62,496.14

What the Data Shows for Zambon USA Ltd.

$62,496.14: that is what Zambon USA Ltd. reported in payments to 99 physicians and teaching hospitals during Program Year 2024, spread across 99 transactions ($631.27 per transaction, $631.27 per recipient). The company sits at rank #1293 of 1,925, a comparatively small 0.0% slice of all industry payments reported nationwide for the year.

The 3-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $56.0K, accounting for 89.6% of this company's General Payments and 57 transactions.

General Payment Breakdown by Type

Zambon USA Ltd. made 3 types of general payments. "Consulting Fee" is the largest category at $56.0K, 89.6% of General Payments.

How Zambon USA Ltd. divides its payments

Top payment categories by total reported dollar volume

1. Consulting Fee$56.0K2. Compensation for Services…$3.4K3. Food and Beverage$3.1K
Payment Type Amount Transactions
Consulting Fee $56.0K 57
Compensation for Services Other Than Consulting $3.4K 1
Food and Beverage $3.1K 41

Recipient Concentration in General Payments

The five largest recipient relationships account for $34,065.19 (54.5%) of $62,496.14 in this company's General Payments records across 39 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Zambon USA Ltd.

The five named recipients with the highest reported General Payments from this company

Brian Keller$7.7KStephen Weigt$7.1KDeborah Levine$6.8KErika Lease$6.7KDiego Caceres$5.8K
  1. 1

    Brian Keller

    $7,700.00 across 2 reported transactions

  2. 2

    Stephen Weigt

    $7,104.09 across 13 reported transactions

  3. 3

    Deborah Levine

    $6,788.41 across 8 reported transactions

  4. 4

    Erika Lease

    $6,669.21 across 7 reported transactions

  5. 5

    Diego Caceres

    $5,803.48 across 4 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Zambon USA Ltd.'s, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Zambon USA Ltd..

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Zambon USA Ltd..

Showing 6 of 1,924 companies with CMS-reported payment data.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Zambon USA Ltd.'s data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.